Acute urinary retention (AUR) is a common complication of benign prostatic hyperplasia (BPH) and the incidence varies widely from 0.4 to 25% per year in men seen in urology practices. It has been estimated that AUR is the indication for surgery in around 25–30% of patients undergoing transurethral resection of the prostate (TURP) and that emergency TURP for AUR is associated with greater morbidity than elective TURP. Risk factors for AUR include lower urinary tract symptoms (LUTS), depressed peak urinary flow rate, enlarged prostate, high postvoid residual (PVR) urine and old age. Alfuzosin has been shown to significantly increase maximum flow rate and relieve bladder outlet obstruction, resulting in a reduction in PVR urine. A pooled analysis of 11 placebo-controlled studies involving 1,470 patients with LUTS suggestive of BPH indicates that significantly greater improvements were observed in patients treated with alfuzosin than with placebo. A 6-month placebo controlled study of 518 patients reported a 0.4% incidence of AUR in the alfuzosin group compared with a 2.4% incidence with placebo (p = 0.04). These positive effects on PVR could be related to the reduction in incidence of AUR seen in alfuzosin-treated patients.

Meigs JB, Barry MJ: The natural history of benign prostatic hyperplasia; in Kirby RS, McConnell JD, Fitzpatrick JM, Roehrborn CG, Boyle P (eds): Textbook of Benign Prostatic Hyperplasia. Oxford, ISIS Medical Media Ltd, 1997, pp 125–135.
Girman CJ, Epstein RS, Jacobsen SJ, Guess HA, Pauser LA, Oesterling JE, Lister MM: Natural history of prostatism: Impact of urinary symptoms on quality of life in 2115 randomly-selected community men. Urology 1994;44:825.
Fowler FJ, Wennberg JE, Timothy RP, Barry MJ, Mullet AG, Hanley D: Symptom status and quality of life following prostatectomy. JAMA 1988;259:3018–3022.
Roberts RO, Jacobsen SJ, Rhodes T, Girman CJ, Guess HA, Lieber MM: Natural history of prostatism: Impaired health states in men with lower urinary tract symptoms. J Urol 1997;157:1711–1717.
Mebust WK, Holtgrewe HL, Cockett ATK, Peters PC, and the Writing Committee: Transurethral prostatectomy: Immediate and postoperative complications. A Cooperative Study of 13 participating institutions evaluating 3,885 patients. J Urol 1989;141:243–247.
Higgins PM, French ME, Chadalavada VS: Management of acute retention of urine: A reappraisal. Br J Urol 1991;67:365–368.
Malone PR, Cook A, Edmonson R, et al: Prostatectomy: Patients’ perception and long-term follow-up. Br J Urol 1988;61:234–238.
Ball AJ, Feneley RC, Abrams PH: The natural history of untreated ‘prostatism’. Br J Urol 1981;53:613–616.
Barry MJ, Fowler FJ, Bin L, Pitts JC, Harris CJ, Mulley AG: The natural history of patients with benign prostatic hyperplasia as diagnosed by North American Urologists. J Urol 1997;157:10–15.
Jacobsen SJ, Jacobsen DJ, Girman CJ, et al: Natural history of prostatism: Risk factors for acute urinary retention. J Urol 1997;158:481–487.
Kohlman C, Girman C, Jacobsen SJ, Guess HA, Lieber MM: Post-void residual urine volume in randomly selected community men in Olmsted County. J Urol 1998;159(suppl 5):139.
Meigs JB, Barry MJ, Giovannucci E, Rimm EB, Stampfer MJ, Kawachi I: Incidence rates and risk factors for acute urinary retention: The Health Professionals Followup Study. J Urol 1999;162:376–382.
ICS: Standardisation of terminology of lower urinary tract function. Neurourol Urodyn 1988;7:403–426.
Rosier PFWM, de Wildt MJAM, de la Rosette JJMCH, Debruyne FMJ, Wijkstra H: Residual urine volume in normal male subjects. J Urol 1995;97:641–645.
Abrams PH, Dunn M, George NJR: Urodynamic findings in chronic retention or urine and their relevance to results of surgery. Br Med J 1979;2:1258–1260.
George NJR, O’Reilly PH, Barnard RJ, Blacklock NJ: High pressure chronic retention. Br Med J 1983;286:1780–1783.
Koch WFRM, El Din KE, de Wildt MJAM, Debruyne FMJ, de la Rosette JJMCH: The outcome of renal ultrasound in the assessment of 556 consecutive patients with benign prostatic hyperplasia. J Urol 1996;155:186–189.
Abrams P, Griffiths D, Buzelin JM, et al: The urodynamic assessment of lower urinary tract symptoms; in Denis L, Griffiths K, Khoury S, Cockett ATK, McConnell J, Chatelain C, Murphy G, Yoshida O (eds): 4th International Consultation on Benign Prostatic Hyperplasia (BPH), Paris, July 2–5 1997, pp 325–377.
Rosier PFWM, de Wildt MJAM, de la Rosette JJMCH, Debruyne FMJ, Wijkstra H: Analysis of maximum detrusor contraction power in relation to bladder emptying in patients with lower urinary tract symptoms and benign prostatic enlargement. J Urol 1995;154:2137–2142.
Bruskewitz RC, Iversen P, Madsen PO: Value of postvoid residual urine determination in evaluation of prostatism. Urology 1982;20:602–604
Birch NC, Hurts G, Doyle PT: Serial residual urine volumes in men with prostatic hypertrophy. Br J Urol 1988;62:571–575.
Mitchell JP: Management of chronic urinary retention. Br Med J 1984;289:515–516.
Jones DA, George JR: Interactive obstructive uropathy in man. Br J Urol 1992;69:337–345.
Turner Warwick RT, Whiteside CG, Arnold EP, et al: A urodynamic view of the prostatic obstruction and the results of prostatectomy. Br J Urol 1973;45:631–645.
Griffiths HJ, Castro J: An evaluation of the importance of residual urine. Br J Radiol 1970;43:409–413.
Griffiths DJ, McCracken PN, Harrison GM, Gormley EA: Characteristics of urinary incontinence in elderly patients studied by 24-hour monitoring and urodynamic testing. Age Ageing 1992;21:195–201.
Abram P, Griffiths DJ: The assessment of prostatic obstruction from urodynamic measurements and from residual urine. Br J Urol 1979;51:129–134.
Elbadawi A: Voiding dysfunction in benign prostatic hyperplasia: Trends, controversies and recent revelations. Urology 1998;51(suppl 5A):62–82.
Cockett ATK, Khoury S, Aso Y, et al: Proceedings of the 3rd International Consultation on Benign Prostatic Hyperplasia. Channel Islands, Scientific Communications International Ltd., 1995, pp 1–651.
Caine M, Pfau A, Perlberg S: The use of alpha-adrenergic blockers in benign prostatic obstruction. Urology 1982;20:524–527.
Perlberg S, Caine M: Adrenergic response of bladder muscle in prostatic obstruction: Its relation to detrusor instability. Urology 1982;20:524–527.
Martorana G, Giberti C, Di Silverio F, et al: Effects of short-term treatment with the α1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia. Eur Urol 1997;32:47–53.
Jardin A, Bensadoun H, Delauche-Cavallier MC, Attali P, and the BPH-ALF Group: Alfuzosin for treatment of benign prostatic hypertrophy. Lancet 1991;337:1457–1461.
McNeill SA, Hargreave TB, Geffriaud-Ricouard C, Santoni J-P, Roehrborn CG: Post-void residual urine in patients with LUTS suggestive of BPH: Pooled analysis of 11 controlled studies with alfuzosin. Urology 2001 (in press).
Lukacs B, Grange JC, Comet D, McCarthy C, and the BPH Group in General Practice: Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in general practice. Prostate cancer and prostate diseases 1998;5:276–293.
Jacobsen SJ, Guess HA, Panser L, et al: A population based study of health care seeking behavior for treatment of urinary syptoms – The Olmsted County Study of Urinary Symptoms and Health Status among Men. Arch Fam Med 1993;2:729–735.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.